Zhejiang Anglikang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Anglikang") held a management meeting on May 26, 2026, where it approved the proposal for joint investment with professional investment institutions. The Company intends to use its own funds to invest 10 million RMB in the Jiangsu Yuanjin Ruihong Venture Capital Partnership (Limited Partnership) (hereinafter referred to as "Jiangsu Yuanjin Ruihong" or "the Partnership"). This matter falls within the authority of the Company's management and does not require submission to the board of directors or shareholders for approval. The details are as follows:
Overview of External Investment
Based on the Company's strategic planning, to further deepen industrial synergy and leverage the capabilities and resource advantages of professional institutions, while focusing on its main business, the Company plans to make equity investments in the healthcare sector and deepen cooperation with high-quality enterprises in the industry to develop and reserve quality innovative drug projects. The Company intends to sign the "Partnership Agreement of Jiangsu Yuanjin Ruihong Venture Capital Partnership (Limited Partnership)" (hereinafter referred to as "the Partnership Agreement") with Shanghai Yuanjin Herun Private Fund Management Co., Ltd. (hereinafter referred to as "Yuanjin Herun") and other partners, using its own funds to invest 10 million RMB in Jiangsu Yuanjin Ruihong. According to the relevant provisions of the "Shenzhen Stock Exchange Stock Listing Rules," "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 7 - Transactions and Related Transactions," and "the Company's Articles of Association," this investment matter falls within the authority of the Company's management and does not require submission to the board of directors or shareholders for approval. This external investment does not constitute a related party transaction and does not constitute a major asset reorganization as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies."
Basic Information of Partners
- General Partner (GP), Executive Partner, Fund Manager: Shanghai Yuanjin Herun Private Fund Management Co., Ltd.
(1) Basic information of Yuanjin Herun as per the National Enterprise Credit Information Publicity System:Name Shanghai Yuanjin Herun Private Fund Management Co., Ltd. Unified Social Credit Code 91310000MABRXE4215 Enterprise Type Limited Liability Company (Natural Person Investment or Holding) Established July 22, 2022 Legal Representative Wan Jin Registered Capital 10 million RMB Registered Location No. 1688, Jinshi Road, Baoshan District, Shanghai Controlling Shareholder, Actual Controller Wan Jin Shareholding Structure Wan Jin holds 80%, Shanghai Yuansheng Wanna Enterprise Management Consulting Partnership (Limited Partnership) holds 20% Business Scope General projects: Private equity investment fund management, venture capital fund management services (must complete registration with the Asset Management Association of China before engaging in business activities). (2) Main Investment Areas: Private equity investment fund management, venture capital fund management services. (3) Registration Status: Yuanjin Herun has registered as a private fund manager with the Asset Management Association of China, registration code P1074153. (4) Whether it is a dishonest executor: Yuanjin Herun is not a dishonest executor.